1. Respiratory Difficulties in Children With Underlying Asthma During Immunotherapy for High-risk Neuroblastoma.
- Author
-
Metrock LK, Qayed M, Simon D, Cash T, O'Connor MG, Johnson S, Esiashvili N, and Katzenstein HM
- Subjects
- Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Child, Preschool, Female, Humans, Immunotherapy, Male, Neuroblastoma diagnosis, Neuroblastoma therapy, Pulmonary Fibrosis diagnosis, Pulmonary Fibrosis etiology, Pulmonary Fibrosis physiopathology, Radiography, Thoracic, Respiratory Function Tests, Tomography, X-Ray Computed, Asthma complications, Neuroblastoma complications, Respiratory Insufficiency diagnosis, Respiratory Insufficiency etiology
- Abstract
Treatment of high-risk neuroblastoma now includes antibody based antitumor immunotherapy as part of standard care. Although this therapy has resulted in dramatic improvements in survival, it is associated with significant side effects. Children with underlying respiratory issues, and in particular asthma, may be more susceptible to immunotherapy associated respiratory compromise and pulmonary complications. Early routine involvement of pulmonology care is warranted for these patients in an effort to allow maximal delivery of immunotherapy and minimize acute and long-term complications.
- Published
- 2017
- Full Text
- View/download PDF